Read more
4:56 PM · 14 December 2022

Will CRISPR Therapeutics benefit from anti-cancer efforts?

-
-
Open account Download free app

The results of CAR-T cells modified with CRISPR Therapeutics' gene editing technology (CRSP.US) according to GlobalData analysts represent a significant step in cancer treatment. Following the recent positive results of Moderna's vaccine and Merck's immunotherapy, came positive news reporting the first gene editing successes against cancer cells. Shares of CRISPR Therapeutics are trading slightly higher:

  • The first patient of the initial phase of the TvT CAR7 trial at UCL Great Ormond Street Insititute of Child Health (GOSH), for the treatment of pediatric acute lymphoblastic leukemia has fought off cancer cells (remission);

Oncology & Hematology analysts at medical market analysis firm GlobalData have already commented on the topic:

"Although the GOSH TvT CAR7 trial has so far produced excellent results in only one patient, this is a significant development - not only for patients with T-ALL (a type of lymphoblastic leukemia) but also for patients with other cancers. If a target can be identified, the CRISPR technology could be used in other blood system diseases besides T-ALL. However, this will take some time, and GlobalData does not forecast the release of a commercial CAR-T product for T-ALL in the near future."

  • The CAR-T cells used in this study, named BE CAR-7, were donated by healthy donors and modified by the company's CRISPR to induce selective toxicity against antigen-positive tumor cells. Previous medical and academic trials have yielded mixed results. Effective therapies that improve patients' overall survival even after relapse.

Crispr Therapeutics (CRSP.US) shares, D1 interval. The price of the company's stock is drawing bullish higher lows and struggling to get above the SMA100 (black line). Source: xStation5

15 January 2026, 3:35 PM

Experimental drug suspended❓💊 Shares od Disc Medicine lose as much as 7% 🚨

15 January 2026, 3:08 PM

Divorce of Europe and the USA over Greenland

15 January 2026, 2:43 PM

US Open: Optimism drives indices on Wall Street📈BlackRock surges after earnings

15 January 2026, 1:38 PM

JP Morgan and Goldman Sachs: Giants after earnings

Join over 2 000 000 XTB Group Clients from around the world

The financial instruments we offer, especially CFDs, can be highly risky. Fractional Shares (FS) is an acquired from XTB fiduciary right to fractional parts of stocks and ETFs. FS are not a separate financial instrument. The limited corporate rights are associated with FS.
This page was not created for investors residing in Brazil. This brokerage is not authorized by the Comissão de Valores Mobiliários (CVM) or the Brazilian Central Bank (BCB). The content of this page should not be characterized as an investment offer in Brazil or for investors residing in that country.
Losses can exceed deposits